TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06452134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
Study: NCT04580485
Drug: INCB106385
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB106385 will be administered orally QD
Study: NCT04580485
Drug: INCMGA00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCMGA0012 will be administered IV once every 4 weeks (Q4W)
Study: NCT06111885
Drug: Indapamide 2.5 MG
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 indapamide 2.5 mg capsule per day for 28 days
Study: NCT06111885
Drug: Chlorthalidone 25mg
Normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 chlorthalidone 25 mg capsule per day for 28 days
Study: NCT06755502
Drug: Calcium Hydroxide, Iodoform, paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metapex as root canal filling materials
Study: NCT06749470
Drug: Jieyu Chufan Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, tid; 8 weeks
Study: NCT06749470
Drug: Jieyu Chufan Capsules simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, tid; 8 weeks
Study: NCT06752577
Drug: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
Study: NCT04929028
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04929028
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05690841
Drug: Focal Mass Drug Administration (fMDA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by regular intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing).
Study: NCT06766929
Drug: VSA012
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06766929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06675175
Drug: AZD4144
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.
Study: NCT04305327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
Study: NCT06744426
Drug: BR1015-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06419608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once daily for 6 weeks
Study: NCT06746831
Drug: 1:1 racemic mixture of two isomers
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg R-Meth + 15 mg S-Meth
Study: NCT04643574
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT06756321
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
Study: NCT06751901
Drug: Neoantigen-based peptide vaccine
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06780644
Drug: Triple combination cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Study: NCT06780644
Drug: Triple combination cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle
Study: NCT06781112
Drug: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined.
Study: NCT00032695
Drug: methionine
Normalized name: Methionine
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05845138
Drug: SHR-A1811 for injection ; capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 for injection; Capecitabine tablets
Study: NCT05612074
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
Study: NCT06309355
Drug: YR001 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is YR001 ointment on a range of body surface area for multiple topical administration
Study: NCT05870748
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.
Study: NCT06335979
Drug: PIT565
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
Study: NCT06792903
Drug: CG101 high dose + artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Study: NCT06792903
Drug: CG101 low dose + artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Study: NCT06792903
Drug: placebo + artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Study: NCT06359665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule twice daily
Study: NCT06630247
Drug: ADC cytotoxic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of anti-cancer combination agent
Study: NCT05603104
Drug: Second-line Antidepressants
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT05603104
Drug: Second-line Antipsychotics
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT06582420
Drug: Standard trauma care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
Study: NCT06792734
Drug: BTM-3566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT06769555
Drug: CM-336 BCMA/CD3 bispecific antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1. For patients achieve hematological PR or better after 2 cycles, and hematological VGPR or better after 4 cycles, the treatment regimen will change to 160mg once every 2 weeks (Q2W).
Study: NCT06594159
Drug: LY4065967
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06594159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06594159
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06801600
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.5% dosage will be calculated and administered intrathecally as 0.4 mg/kg or 0.08 ml/kg if body weight ≤ 15 kg and 0.3 mg/kg or 0.06 ml/kg if body weight \> 15 kg
Study: NCT06801405
Drug: antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis before percutaneous nephrostomy
Study: NCT06785753
Drug: Irrigation Solution
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline will be used as irrigation solution
Study: NCT06194799
Drug: ACP-204
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Study: NCT06566079
Drug: ISM6331
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment.
Study: NCT06713317
Drug: HLB3-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Hyaluronidase
Study: NCT06713317
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal saline
Study: NCT05423717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken orally, once daily in the evening during the treatment period.
Study: NCT05754983
Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study
Normalized name: The New Parent First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
Study: NCT06339788
Drug: HD-P023
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of HD-P023
Study: NCT06655272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT06589986
Drug: RO7790121
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
Study: NCT06589986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching IV RO7790121. Placebo matching SC RO7790121.
Study: NCT06768905
Drug: Iomab-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.
Study: NCT06745336
Drug: CS-001
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-001 Topical Treatment
Study: NCT06745336
Drug: Placebo Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Solution
Study: NCT06642545
Drug: Albumin-bound Paclitaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m2,intravenous infusion, D1-8, every 3 weeks
Study: NCT06719544
Drug: enlicitide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06780033
Drug: ART-101 - SAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Forty participants will be enrolled across 5 SAD cohorts. The planned doses across 5 cohorts are as follows- include 20mg (SAD Cohort 1), 60mg (SAD Cohort 2). 150mg (SAD Cohort 3). 300mg (SAD Cohort 4) and 500 mg (SAD Cohort 5).
Study: NCT06300463
Drug: AGEN1423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg IV Q3W
Study: NCT06037980
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
Study: NCT05843786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during 5 days
Study: NCT04699747
Drug: F-18 3F4AP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
Study: NCT05270525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
Study: NCT04539366
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06800651
Drug: Plcacebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched to JMKX003142
Study: NCT06793358
Drug: fentanyl and Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is the first dental study that will combine these two sedation drugs
Study: NCT06752486
Drug: Giving post photorefractive keratectomy for pain relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
Study: NCT06724016
Drug: HM16390
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
Study: NCT05507970
Drug: MMV367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose dispersed in sterile water, fasted.
Study: NCT05507970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose dispersed in sterile water, fasted.
Study: NCT05507970
Drug: MMV367 (Fed 440mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose dispersed in sterile water with a high fat meal.
Study: NCT05507970
Drug: MMV367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Study: NCT05507970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Study: NCT05514353
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Vehicle Cream formulation contains the same excipients as the active cream
Study: NCT05349006
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
Study: NCT04468360
Drug: Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
Study: NCT06723080
Drug: VC005 Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 Placebo group repeat administration
Study: NCT06070857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
Study: NCT06754462
Drug: IMVT-1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once weekly by subcutaneous injection.
Study: NCT06754462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once weekly by subcutaneous injection.
Study: NCT06687941
Drug: AST-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
Study: NCT05701917
Drug: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants are a group of medications that decrease your blood's ability to clot.
Study: NCT06725017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05417321
Drug: HB0036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
Study: NCT06192615
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo of 0.9% saline administered over 40 minutes
Study: NCT06192615
Drug: Sublingual Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert sublingual film
Study: NCT05485805
Drug: Naproxen sodium and caffeine (BAY2880376)
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral use, single dose
Study: NCT05485805
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral use, single dose
Study: NCT05485805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use, single dose
Study: NCT06440005
Drug: AGX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody Drug Conjugate
Study: NCT04755595
Drug: Botox Cosmetic Injectable Product
Normalized name: Botox Cosmetic Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine release inhibitor and a neuromuscular blocking agent
Study: NCT06792695
Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI will be administered as IV infusion.
Study: NCT06024408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
Study: NCT05849727
Drug: TQH3821 tablets 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
Study: NCT05849727
Drug: TQH3821 tablets matching placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH3821 tablets matching placebo without active substance.
Study: NCT06761586
Drug: AUR104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice a day
Study: NCT06760546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to setmelanotide for daily subcutaneous injection
Study: NCT06779149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to this group will be prescribed 5 to 10 mg of placebo to be taken at bedtime in 5 mg capsules identical to lemborexant. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.